4280. Package # 678.1 (Cervical pathology screening: PAP test using liquid cytology (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved), PCR. HPV 28 (genotyping, qualitative determination), PCR. Screening 7 STI)
Turnaround time (days): 3
2660 ₴
Important information
*FOR WOMEN ONLY
*An operator specifies the day of the menstrual cycle or the gestational age
*For the test ordering a special doctor's referral is required
Description
A comprehensive solution for the diagnosis of cervical pathologies that allows simultaneous assessment of epithelial cell condition, detection of the presence and type of human papillomavirus (HPV), and identification of the most common sexually transmitted infections (STIs). This integrated approach provides the most complete information and helps the physician choose the optimal patient management strategy.
The package includes: Pap test using BD SurePath™ liquid-based cytology with automated BD FocalPoint™ analysis (Cytology Passport) – a modern, high-precision method for early detection of precancerous and malignant changes of the cervix.
At Synevo, the test is performed using the dual-expertise principle:
- by experienced cytologists;
- with the BD FocalPoint™ GS Imaging System (Becton Dickinson, USA) – a digital microscopy system based on artificial intelligence – combined with a ZEISS Axioscope 5 microscope (Carl Zeiss, Germany).
This approach significantly increases the sensitivity and reliability of detecting abnormal cells, allowing diagnosis at early stages when treatment is most effective. HPV PCR test for 28 genotypes (qualitative determination with genotyping) – the study covers 19 high-risk carcinogenic genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82) and 9 low-risk genotypes (6, 11, 40, 42, 43, 44, 54, 61, 70), which primarily cause benign lesions (condylomas). The test allows detection of HPV presence, identification of the specific genotype, and assessment of the risk of developing precancerous conditions depending on the virus type.
PCR screening for 7 STIs – detects the most common infections that can cause inflammation and complicate the course of HPV infection:
- Chlamydia trachomatis.
- Neisseria gonorrhoeae.
- Mycoplasma genitalium.
- Mycoplasma hominis.
- Ureaplasma urealyticum.
- Ureaplasma parvum.
- Trichomonas vaginalis.
Timely diagnosis of these infections helps prevent complications (chronic cervicitis, infertility, pregnancy complications) and improves the accuracy of differential diagnosis in cases with atypical cytology results.
Learn more about the technology and the Cytological Passport.
When and who needs the test?
- For women starting from the onset of sexual activity.
- Annually – from age 21, or every 2-3 years if three consecutive results are negative.
- In the presence of cervical abnormalities or a positive HPV test result.
- In cases of recurrent inflammatory processes, abnormal discharge, pain syndrome, dyspareunia, or before planning pregnancy.
- As part of routine preventive (dispensary) follow-up.
Biological material
- Site-specific scrapings collected depending on the test
- Scrapes from various sites depending on the test
Preparing for urogenital sampling
- Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
- In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
- Avoid sexual intercourse for 3 days.
- Exclude douching and the use of vaginal...